iRegene Therapeutics secures series B+ financing

NouvNeu001 is the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive this designation

iRegene Therapeutics (Chengdu) Co., a biotechnology company pioneering chemically induced allogeneic cell therapies, announced the successful completion of its Series B+ financing round. The round was co-led by Northern Light Venture Capital, Chuangjing Capital, and OneHealth Haihe Capital, with participation from additional investors.

This financing follows a major milestone achieved in August 2025, when the U.S. Food and Drug Administration (FDA) granted Fast Track Designation (FTD) to NouvNeu001, iRegene’s lead program for Parkinson’s disease. NouvNeu001 is the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive this designation, marking a significant step forward for both the Company and the field of regenerative medicine.

With this latest round, iRegene’s cumulative funding has exceeded RMB 300 million (approximately USD 40 million), representing the largest single financing in China’s iPSC sector in recent years. The investment underscores strong confidence from global investors in iRegene’s leadership and long-term strategic vision.

The proceeds will be used to advance the global clinical development of NouvNeu001 for Parkinson’s disease and NouvSight001 for retinal degenerative diseases. In addition, the Company will strengthen its early-stage research pipeline, expand its clinical and operational teams, and enhance its manufacturing capabilities to support future growth.